An interchangeable biosimilar product can be substituted for its reference product without a physician. Pharmacists can substitute the drug at a pharmacy, similar to the way generic drugs are substituted for brand-name drugs.
The reference product for Semglee is Lantus, a long-acting insulin made by Sanofi.
Semglee is designed to treat both adult and pediatric patients with Type 1 diabetes, as well as adults with Type 2 diabetes. More than 34 million people in the U.S. have been diagnosed with diabetes, according to the FDA.
“This is a momentous day for people who rely daily on insulin for treatment of diabetes, as biosimilar and interchangeable biosimilar products have the potential to greatly reduce healthcare costs,” acting FDA Commissioner Janet Woodcock, MD, said in a news release.
Biosimilar and interchangeable drugs have the potential to reduce costs, as they’re cheaper than the original brand-name drug, similar to how generic drugs reduce costs.
Read the FDA’s full news release here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.